This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Arcturus Remove Equity Remove San Diego Related Topics
Capital Blogging Venture Capital Funding Marketing Startup Develop Google Activity Development More Related Topics >
article thumbnail

Sorrento Therapeutics Gets $2.3M

socalTECH

JUNE 19, 2009

San Diego-based Sorrento Therapeutics , a new biotechnology startup, has raised $2.3M in an equity funding round, according to a regulatory filing by the firm yesterday. Dr. Schuh was previously CEO and Director of AviaraDx, and also served at Arcturus Bioscience and Sequenom. Source of the funding was not disclosed.

Arcturus 100
Arcturus San Diego Venture Capital Equity 100
article thumbnail

Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More

Xconomy

APRIL 17, 2020

The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn’t the only way for biotech companies to raise cash. Late last year Alnylam (NASDAQ: ALNY ) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol.

Equity 84
Equity Activity Marketing Company 84
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 5,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024